Overview
Rohit K. Singla is a litigation partner who focuses on antitrust, intellectual property and complex employment disputes at trial and appeal.
He represents clients in matters involving a wide range of technologies, including software, entertainment, videogames, on-demand services, pharmaceuticals and medical devices.
Before pursuing a career in law, Rohit spent two years with McKinsey & Company’s Knowledge Management group in New York.
Experience
Antitrust
Rohit’s antitrust work includes representing clients in cases involving monopolization, horizontal and vertical conspiracies, sham petitioning, resale price maintenance and Robinson-Patman Act violations. He has a particular specialty in issues at the intersection of antitrust and intellectual property, such as antitrust challenges to so-called reverse payment patent settlements, claims of sham patent litigation, technological tying claims and intellectual property defenses to antitrust claims. He was co-lead counsel for the defense in FTC v. Actavis, the seminal Supreme Court case that set the legal standard for antitrust challenges to patent settlements.
Key antitrust representations include:
Amgen, Inc. in antitrust cases challenging its licensing, prosecution and enforcement of patents over the drug Enbrel.
Leading AI company in strategic counseling regarding worldwide regulatory efforts.
AbbVie as lead counsel in defense of claims by the Federal Trade Commission and MDL class actions asserting antitrust challenges to patent settlements. The matter included the landmark FTC v. Actavis decision by the United States Supreme Court.
NCAA as trial counsel in a nationwide class action asserting antitrust and intellectual property claims relating to NCAA rules that allegedly preclude collegiate basketball and football athletes from being paid for the alleged use of their name, image and likeness.
Lyft Inc. with respect to an antitrust challenge to its hiring and pricing practices brought by a purported class of private car service providers.
Takeda Pharmaceuticals as lead counsel in purported antitrust MDL class actions brought by direct and indirect purchasers of Actos in the U.S. District Court for the Southern District of New York.
Mutual Pharmaceuticals in obtaining denial of class certification to two proposed classes of indirect purchasers alleging that its licensing and enforcing of patents delayed entry into the market of a generic version of the muscle relaxant Skelaxin.
Brighton Collectibles as national antitrust counsel defending against class action challenges to alleged resale price maintenance agreements; obtained dismissals in Tennessee, Texas and Kansas trial and appellate courts, on remand from landmark U.S. Supreme Court decision.
Intellectual Property Litigation
Rohit has significant intellectual property experience in a range of areas including patent litigation, copyright, Digital Millennium Copyright Act (DMCA) and trade secret claims. Rohit was lead appellate counsel in Therasense Inc. v. Becton, Dickinson, in which the en banc Federal Circuit reformed the doctrine of inequitable conduct.
Abbott Laboratories in a patent licensing dispute involving DNA replication technology used in the ID Now diagnostic system, which was the first approved diagnostic test for COVID-19.
Microsoft in wide-ranging intellectual property and antitrust litigation concerning technological measures in the Xbox 360 videogame console designed to preclude unauthorized accessories. The litigation included DMCA, copyright, trade secret, patent, design patent, trademark and Kodak “aftermarket” antitrust claims.
MPAA co-lead trial counsel in precedent-setting DMCA and antitrust and copyright dispute over the “RealDVD” copying system developed by Real Networks.
Employment Classification Litigation
Rohit’s employment work focuses on representing technology companies in large, complex misclassification disputes that involve government investigations, government enforcement actions and private plaintiff cases.
Lyft Inc. in numerous misclassification actions across the country, including leading the defense team in the largest trial of such issues to date.
Angi, Inc. in the defense of a preliminary injunction sought by California district attorneys seeking to force the reclassification of independent service professionals as employees.
Instacart in misclassification and arbitration disputes.
More
- Consistently ranked in Chambers USA for Antitrust
- California Lawyer Attorney of the Year (CLAY) for historical litigation against the City and County of Los Angeles that led to a preliminary injunction eliminating cash bail for individuals arrested on most low-level, non-violent offenses, Daily Journal, 2024
- Top Labor and Employment Lawyer in California, Daily Journal, 2022-2023
- Top Antitrust Lawyer, Daily Journal, 2022
- Keta Taylor Colby Award, Lawyers Committee for Civil Rights of San Francisco, for helping to secure a historic victory ending warrantless parking ticket tows in San Francisco and across California, 2024
- 500 Leading Litigators in America, Lawdragon, 2025
- Board of Directors and past board chair, Lawyers’ Committee for Civil Rights of the San Francisco Bay Area
- Board of Directors and Treasurer, Public Advocates, a public interest law firm
Rohit has an active pro bono practice that has recently included the representation of more than a dozen families that were separated at the border during the first Trump administration, an appeal establishing the Fourth Amendment rights of poor people in California whose cars are seized by the government, a lawsuit successfully challenging the century-old bail system in California that keeps poor people in jail merely because they cannot afford bail and a suit seeking to vindicate the right of access to juvenile dependency proceedings in North Carolina.
Publications
- Co-author, “Calif. Antitrust Laws May Turn More Zealous Than US Regs,” Law360, April 16, 2025
- Quoted, “How Sham Patents Are Hurting the Pharma Industry,” Pharmaceutical Technology, May 7, 2024
- Quoted, “US FTC Delivers on Orange Book Threat,” BioWorld, Nov. 8, 2023
- Quoted, “Biden Admin Enlists the Orange Book to Tackle Drug Pricing,” Politico Prescription Pulsenewsletter, Sept. 15, 2023
- Quoted, “Merger Guidelines Update to Bring Some Clarity Amid Declining M&A,” Policy and Regulatory Report and Dealreporter, April 2023
- Quoted, “US DOJ’s Move to Oust Overlapping Board Members Comes After Years of Limited Enforcement,” MLex Market Insight, Nov. 2, 2022
Speaking Engagements
- Speaker, “Can Your Client (Anti)Trust You? How to Hatch Your Plan for a Procompetitive Settlement Agreement,” NAPABA Convention, November 5, 2022
- Panel member, “Antitrust in Higher Education,” ABA Antitrust Law Section Spring Meeting, 2023
- Speaker, “Inequitable Conduct After Regeneron: What Litigators, Patent Prosecutors and Patent Owners Need to Know,” IP Chat Channel Webinar, Intellectual Property Owners Association, January 2019
- Panel member, “Mock Trial: FTC v. Actavis,” ABA Antitrust Law Section Spring Meeting, 2014
